APT THERAPEUTICS, INC.
Naperville, IL · Biotech · Private
APT402, a fusion protein combining apyrase and annexin V for antiplatelet, anticoagulant, and cardioprotective activity in acute myocardial infarction
- Grants
- $17M
- 23 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 9
- 0 granted · 9 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201420162018202020222024
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Human Apyrase Therapy for Diabetic Neuropathic Pain | $299,793 | |
| Federal grant | Department of Health and Human Services · Phase I · Low-dose IL-2-based Immunomodulatory Therapy for PAH | $297,410 | |
| Federal grant | Department of Health and Human Services · Phase I · Optimized IL2-based Therapy for Type 1 Diabetes | $298,486 | |
| Federal grant | Department of Health and Human Services · Phase I · IL2-based Immunotherapy for Type 2 Diabetes | $299,200 | |
| Federal grant | Department of Health and Human Services · Phase I · Human Apyrase Therapy for Acute Ischemic Stroke | $2,736,786 | |
| Federal grant | Department of Health and Human Services · Phase I · IL2-based Immunotherapy for Lupus | $225,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Antithrombotic Therapy with No Bleeding Risk for PCI | $1,902,274 | |
| Federal grant | Department of Health and Human Services · Phase II · Antithrombotic Therapy with No Bleeding Risk for PCI | $300,437 | |
| Federal grant | Department of Health and Human Services · Phase I · Immunomodulatory Therapy for Diabetic Nephropathy | $279,040 | |
| Federal grant | Department of Health and Human Services · Phase I · Synergistic Anti-tumor Efficacy of an Interleukin 2 Analog and PD-1 blockade | $299,794 | |
| Federal grant | Department of Health and Human Services · Phase I · Immunomodulatory Therapy for Neuropathic Pain | $299,346 | |
| Federal grant | Department of Health and Human Services · Phase I · Prevention of Post-MI Heart Failure with Immunomodulatory Therapy | $337,602 | |
| Federal grant | Department of Health and Human Services · Phase II · Antithrombotic Therapy with No Bleeding Risk for PCI | $723,518 | |
| Federal grant | Department of Health and Human Services · Phase I · Combination treatment with tPA and IL2 analog for Stroke | $344,933 | |
| Federal grant | Department of Health and Human Services · Phase I · Synergistic Efficacy of an Interleukin 2 Analog and Antitumor Antigen Antibody | $300,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Anti-inflammatory and Anti-diabetic Therapy for Metabolic Syndrome | $300,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Peripherally Acting Analgesic for Osteoarthritis Pain | $259,576 | |
| Federal grant | Department of Health and Human Services · Phase II · Immunomodulatory Therapy for Neuropathic Pain | $996,399 | |
| Federal grant | Department of Health and Human Services · Phase II · Immunomodulatory Therapy for Neuropathic Pain | $922,476 | |
| Federal grant | Department of Health and Human Services · Phase II · Multi-functional anti-thrombotic therapy for coronary microvascular obstruction | $1,582,022 | |
| Federal grant | Department of Health and Human Services · Phase II · Immunomodulatory Therapy for Neuropathic Pain | $501,320 | |
| Federal grant | Department of Health and Human Services · Phase II · Multi-functional anti-thrombotic therapy for coronary microvascular obstruction | $1,360,862 | |
| Federal grant | Department of Health and Human Services · Phase II · Multi-functional anti-thrombotic therapy for coronary microvascular obstruction | $1,717,926 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2323 | SUS CLINICALS INC | — | $3.5M |
| 2324 | Myricx Bio | — | — |
| 2325 | Abiologics | — | — |
| 2326 | APT THERAPEUTICS, INC. | — | — |
| 2327 | Landos Biopharma | — | $60M |
| 2328 | RESVITA BIO, INC. | — | — |
| 2329 | CALLENTIS CONSULTING GROUP LLC | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Synergistic And Targeting Compositions For Treatment Of Arterial And Venous Thrombosisapplication
- Adp'ase-enhanced Apyrase Therapy For Wounds, Microbial Infection, Sepsis, And Heterotopic Ossificationapplication
- Adp'ase-enhanced Apyrase Therapy For Wounds, Microbial Infection, Sepsis, And Heterotopic Ossificationapplication
- Apyrase Therapy For Fibroproliferative Disorders, Pulmonary Hypertension, And Heart Failureapplication
- Therapeutic Apyrase Constructs, Apyrase Agents, And Production Methodsapplication
- Apyrase Therapy For Bleeding Conditionsapplication
- Design And Therapeutic Use Of Adpase Enhanced Apyrasesapplication
- Calculating A Characteristic Property Of A Molecule By Correlation Analysisapplication
- Calculating A Biological Characteristic Property Of A Molecule By Correlation Analysisapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.